PURPOSE: To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites. The study was also intended to assess whether temozolomide affects the conversion of irinotecan to SN-38. DESIGN: Patients with recurrent malignant glioma received a fixed dose of temozolomide (150 mg/m(2)) daily for 5 days from days 1 to 5 every 28 days, and an i.v. infusion of irinotecan on days 1 and 15 of each cycle. The starting dose of irinotecan was 350 mg/m(2), which was escalated to 550 mg/m(2) in 50-mg/m(2) increments. The plasma pharmacokinetics of irinotecan and its active metabolite, SN-38, were determined during the infusion of irinotecan on cycle 1, day 1. RESULTS: Thirty-three patients were enrolled into the study and treated. Thirty-one patients were evaluable for both tumor response and toxicity and two patients were evaluable for toxicity only. Common toxicities included neutropenia and thrombocytopenia, nausea, vomiting, and diarrhea. Dose-limiting toxicities were grade 3 diarrhea and nausea/vomiting. The maximum tolerated dose for irinotecan was determined to be 500 mg/m(2). CONCLUSIONS: The recommended phase II dose of irinotecan in combination with temozolomide for patients receiving EIAEDs is 500 mg/m(2), administrated every 15 days on a 28-day schedule. This study also confirmed that concomitant administration of EIAEDs increases irinotecan clearance and influences SN-38 disposition. No pharmacokinetic interaction was observed between temozolomide and irinotecan.
PURPOSE: To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites. The study was also intended to assess whether temozolomide affects the conversion of irinotecan to SN-38. DESIGN:Patients with recurrent malignant glioma received a fixed dose of temozolomide (150 mg/m(2)) daily for 5 days from days 1 to 5 every 28 days, and an i.v. infusion of irinotecan on days 1 and 15 of each cycle. The starting dose of irinotecan was 350 mg/m(2), which was escalated to 550 mg/m(2) in 50-mg/m(2) increments. The plasma pharmacokinetics of irinotecan and its active metabolite, SN-38, were determined during the infusion of irinotecan on cycle 1, day 1. RESULTS: Thirty-three patients were enrolled into the study and treated. Thirty-one patients were evaluable for both tumor response and toxicity and two patients were evaluable for toxicity only. Common toxicities included neutropenia and thrombocytopenia, nausea, vomiting, and diarrhea. Dose-limiting toxicities were grade 3 diarrhea and nausea/vomiting. The maximum tolerated dose for irinotecan was determined to be 500 mg/m(2). CONCLUSIONS: The recommended phase II dose of irinotecan in combination with temozolomide for patients receiving EIAEDs is 500 mg/m(2), administrated every 15 days on a 28-day schedule. This study also confirmed that concomitant administration of EIAEDs increases irinotecan clearance and influences SN-38 disposition. No pharmacokinetic interaction was observed between temozolomide and irinotecan.
Authors: M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen Journal: Ann Oncol Date: 2001-02 Impact factor: 32.976
Authors: C B Hare; G B Elion; P J Houghton; J A Houghton; S Keir; S L Marcelli; D D Bigner; H S Friedman Journal: Cancer Chemother Pharmacol Date: 1997 Impact factor: 3.333
Authors: Timothy F Cloughesy; Emese Filka; Gillian Nelson; Fairooz Kabbinavar; Henry Friedman; Langdon L Miller; Gary L Elfring Journal: Am J Clin Oncol Date: 2002-04 Impact factor: 2.339
Authors: E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton Journal: Br J Cancer Date: 1992-02 Impact factor: 7.640
Authors: E J Estlin; L Lashford; S Ablett; L Price; R Gowing; A Gholkar; J Kohler; I J Lewis; B Morland; C R Pinkerton; M C Stevens; M Mott; R Stevens; D R Newell; D Walker; C Dicks-Mireaux; H McDowell; P Reidenberg; P Statkevich; A Marco; V Batra; M Dugan; A D Pearson Journal: Br J Cancer Date: 1998-09 Impact factor: 7.640
Authors: Alexander K Berg; Jan C Buckner; Evanthia Galanis; Kurt A Jaeckle; Matthew M Ames; Joel M Reid Journal: J Clin Pharmacol Date: 2015-06-26 Impact factor: 3.126
Authors: Frank S Lieberman; Meihua Wang; H Ian Robins; Christina I Tsien; Walter J Curran; Maria Werner-Wasik; Ryan P Smith; Christopher Schultz; Alan C Hartford; Peixin Zhang; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-27 Impact factor: 7.038
Authors: Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman Journal: J Neurooncol Date: 2009-06-17 Impact factor: 4.130
Authors: Marta Santisteban; Jan C Buckner; Joel M Reid; Wenting Wu; Bernd W Scheithauer; Matthew M Ames; Sara J Felten; Daniel A Nikcevich; Martin Wiesenfeld; Kurt A Jaeckle; Evanthia Galanis Journal: J Neurooncol Date: 2008-12-10 Impact factor: 4.130